Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients

Jabir, Nasimudeen R.; Firoz, Chelapram K.; Kamal, Mohammad Amjad; Damanhouri, Ghazi A.; Alama, Mohammed Nabil; Alzahrani, Anas S.; Almehdar, Hussein A.; Tabrez, Shams

doi:10.1002/jcla.22092

Cited by 22 publications

(25 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Taken together all above mentioned facts, increased IL-10 levels in CVD patients could be a compensatory response against the elevation of pro-inflammatory mediators and vascular injury. We also observed a significant rise in these mediators in our previous studies (15,34).…”

Section: Discussionsupporting

confidence: 84%

“…In our earlier studies, we reported non‐significant associations of SNPs in promoter region of IL‐6, IL‐18, and IL‐1β genes with Saudi CVD patients . However, the present study reports a significant association between polymorphism in IL‐10 promoters at −1082 and −819 sites with Saudi CVD patients.…”

Section: Discussioncontrasting

confidence: 78%

“…In our earlier studies, we have reported a significant elevation in different inflammatory mediators such as IL‐6, IL‐18, and IL‐1β in Saudi CVD patients . In this study too, we observed a significant elevation in IL‐10 level in CVD patients and other cardiac events (Table ).…”

Section: Discussionsupporting

confidence: 68%

See 2 more Smart Citations

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

et al. 2017

Self Cite

View full text Add to dashboard Cite

Interleukin-10 (IL-10) is an anti inflammatory cytokine involved in the ongoing coronary inflammation and related patho-physiological processes. The piece of work presented herein is aimed at investigating possible association of polymorphisms in IL-10 promoter with Saudi cardiovascular disease (CVD) patients. The study included 80 confirmed CVD patients with diabetes and 75 healthy control individuals both men and women. Concentration of IL-10 in the serum samples were measured by ELISA method. For single nucleotide polymorphism (SNP) analysis, Sanger method of DNA sequencing was followed. The IL-10 level was found to be significantly elevated in CVD patients (P < 0.001) and its associated complications viz. ST-elevation myocardial infarction [STEMI] (P <0.01), non ST-elevation myocardial infarction [NSTEMI] (P < 0.05), and unstable angina [UA] (P < 0.001). We also observed a significant association between polymorphisms in IL-10 promoter at -1082 and -819 locus with Saudi CVD patients. Moreover, at -1082 A/G locus, AA haplotype was found to be less frequent in the CVD patients compared with control individuals. On the other hand, highly significant rise in heterozygous (A/G genotype) condition was observed in patient samples compared with control ones (P < 0.001). Similarly, the genotypic frequencies at -819 C/T locus were also found to be significantly associated (P < 0.001) with CVD patients compared with control individuals. Our study provides the status of polymorphism in IL-10 promoter and its association with CVD risk in Saudi population. As per our information, ours is the first article that shows the genetic diversity in IL-10 promoters and its level in the Saudi CVD patients. © 2017 IUBMB Life, 69(7):522-527, 2017.

show abstract

Section: Discussionsupporting

confidence: 84%

Section: Discussioncontrasting

confidence: 78%

See 1 more Smart Citation

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

et al. 2017

Self Cite

View full text Add to dashboard Cite

show abstract

“…Numerous studies have been carried out to evaluate the association of gene polymorphisms to the onset of type 2 diabetes, while only a few were done to reveal their relation with secondary complications [Tsiavou et al, ; Arababadi et al, ]. Jabir et al has studied SNP at ‐174 G/C promoter site in coronary artery disease patients and has reported increased IL‐6 level [Jabir et al, ]. To the best of our knowledge, this is the first study which was designed to evaluate the polymorphism in the ‐590 region of IL‐4 gene and ‐176 region of IL‐6 gene in type 2 diabetic patients with CKD (stage 2–4) in North Indian populations.…”

Section: Discussionmentioning

confidence: 99%

Study of IL4‐590C/T and IL6‐174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population

Neelofar

Ahmad

et al. 2017

J of Cellular Biochemistry

View full text Add to dashboard Cite

To explore the associations between potential functional promoter polymorphisms in pro-inflammatory and anti-inflammatory (IL-4(-590C/T) and IL-6(-174G/C) cytokine genes, and kidney dysfunction in North Indian type 2 diabetic subjects with chronic kidney disease. A total of 150 subjects aged 25-75 year were included in this study. The glomerular filtration rate (GFR) and serum creatinine were estimated. PCR was performed to analyse genotype distribution in IL-4 (-590T/C) and IL-6 (-174G/C) among healthy, type 2 diabetic patients with or without CKD. The genotype distributions were determined by Hardy-Weinberg equilibrium. CKD patients showed lower GFR (59.36 ± 1.33 ml/min/1.73 m ) and higher serum creatinine (1.93 ± 0.99% mg) level in comparison to diabetic patients without CKD and healthy subjects. Genotypic distribution of the different genotypes among the study groups in IL-4 gene was genotype CC = 30, TC = 12, and TT = 8 in CKD patients. In type 2 diabetic patients without CKD, genotype distribution was CC = 38, TC = 10, and TT = 2. In healthy subjects, distribution of genotype was CC = 35, TC = 14, and TT = 1. The distribution of different genotype among the study groups for IL-6 gene was GG = 27, GC = 20, and CC = 3 in healthy subjects; GG = 28, GC = 19, and CC = 3 in diabetic patients without CKD and GG = 38, GC = 11, and CC = 1 in diabetic patients with CKD. There was no significant difference in the distribution of genotype frequencies between healthy subjects and diabetic patients without CKD but a significant difference was found in diabetic patients with CKD. The functional promoter polymorphisms IL4-590C/T and IL6-174G/C, which affect the IL-4 and IL-6 levels in north Indian subjects, were associated with kidney dysfunction and CKD. J. Cell. Biochem. 118: 1803-1809, 2017. © 2016 Wiley Periodicals, Inc.

show abstract

“…The purification of PCR products was carried out by using PCR purification kit (Thermo Scientific). The subsequent positive DNA clones were sequenced and analyzed as described in Jabir et al [2016aJabir et al [ , 2017.…”

Section: Dna Sequencing and Analysismentioning

confidence: 99%

Estimation of Interleukin-1β Promoter (−31 C/T and −511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

Interleukin-1β (IL-1β) is an inflammation-causing cytokine that exerts several unique biological effects and could lead to future adverse events of CAD. The piece of work presented herein is aimed at investigating possible association of IL-1β levels to its polymorphic site viz. -511 and -31 at promoter region in Saudi CAD patients. The study included 155 confirmed CAD patients and 80 healthy control individuals both men and women. Concentration of IL-1β in the patients' serum was measured by ELISA method. For single nucleotide polymorphism (SNP) analysis, sanger method of DNA sequencing was followed. We observed variable numbers of SNPs at -31 C/T and -511 T/C promoter regions in Saudi patients suffering from CAD in comparison to the control set of individuals. However, the changes in the number of SNP-hotspots were determined to be non-significant with reference to the control set. The haplotype analysis at -31 and -511 also did not show any significant changes between control and CAD patients. Moreover, serum IL-1β levels were observed to be expressively higher in patients suffering from CAD (P < 0.001) and its associated complications viz. STEMI (P < 0.001), NSTEMI (P < 0.001), and UA (P < 0.001). Our study provides the status of SNPs at IL-1β promoter in Saudi population. As per our information, ours is the first article that shows the genetic diversity in IL-1β promoters and its level in the Saudi CAD patients. J. Cell. Biochem. 118: 2977-2982, 2017. © 2017 Wiley Periodicals, Inc.

show abstract

Assessment of genetic diversity in IL-6 and RANTES promoters and their level in Saudi coronary artery disease patients

Cited by 22 publications

References 45 publications

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

A putative association of interleukin‐10 promoter polymorphisms with cardiovascular disease

Study of IL4‐590C/T and IL6‐174G/C Gene Polymorphisms in Type 2 Diabetic Patients With Chronic Kidney Disease in North Indian Population

Estimation of Interleukin-1β Promoter (−31 C/T and −511 T/C) Polymorphisms and Its Level in Coronary Artery Disease Patients

Contact Info

Product

Resources

About